NTM Infections Market: Emerging Opportunities 🌍 Nontuberculous mycobacterial (NTM) infections are an increasing global health challenge, with rising prevalence among older adults and immunocompromised patients. In the U.S., cases surpassed 108,000 in 2023, driving a treatment market worth nearly USD 360 million. ARIKAYCE leads with strong sales, while pipeline therapies like SPR720, MNKD-101, and Epetraborole promise to reshape the landscape. Growing awareness, advanced diagnostics, and innovative therapeutics are fueling significant growth prospects through 2034. 👉Discover detailed insights, key companies, and future forecasts here: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=mpr